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C'hapte r 8
8.1 Ang-(1-7): a versati le modulator of the renin-angiotcnsin sy'stem
ln this thesis, i t  is den.ronstrated that Ang-(l-7) modulates the RAS activi ty by an-
tagonizing Ang l l- induced vasoconstr ict ions in a variety of lvays. and inhibit ing ACE
act i r . i t y .  Inh ib i t ion  o f  ACh,  wh ic l i  degrades  Ang- ( l -7 )  to  the  inac t ive  Ang- ( l -5 ) ,  by
l i s inopr i l  improves  t l ie  an tagon iz ing  e f fcc t  o f  Ang- ( l -7 )  on  Ang l l - induced vascon-
str ict ior.rs. This chaptcr prcsents an outl inc of the rat ionalcs that lcd to the studies dc-
scribed in t l .us thesis, and is a sumurary o1'the f indings. In adcl i t ion, some considera-
t ions fbr future studies are indicated.
At thc starl  of the studics on huntan at leries, prcscnted in this thesis, thc effect of
Ang-(l-7) on RAS activi ty in huntaus \\ ,as not knorvt.t .  Frorn the l i teraturc, i t  r .vas
knor,r 'n that Ang-(1-7) coulcl antagonize Ang II- inducecl vasocontr ict ions in r-abbit
i iorta and inhibit  the activi ty of isolated canine ACE.. Clearly, this rvas r.rot suff icient to
pred ic t  the  ro le  o f  Ang- ( l -7 )  in  hurnan vascu la r  func t ion ,  and a  sc t  o Í 'exper iments
rvas planned to obtai l l  a bettel insight into this nt i l t ter.
In Chapters 2 and 3, the eUèct of Ang-(l-7) on RAS activi ty in hunan arterics,
plasnra. and cardiac t issne rvas explored. The data shorv that Ang-(1-7) antagonizes
Ang l l - i r r t luced vasoconst r i c t ions  in a  l ron-conrpc t i t i ve  uay  (Chapter  I  &  3) .  Funher -
more, Ang-( l-7) inhibits plasnra. cardrac t issue, and vascular t issue ACE activi ty
(Chapter 3). Ang-(t-7) had a grcater aÍÍ ini ty for ACll  than Ang I (Chapter 3). The
latter result indicatcs that Ang-(l-7) may be au inrpofiartt  conrpeti tor of Ang I for
binding to ACII.  Because ACE inhibit ion augl.nents Ang-(1-7) lc ' ' 'c ls, a consequcncc
of ledr-rced Ang-(l-7) breakdown, Ang-(l-7) t .nay have a signif icant bystander efÍèct
in patients treated rvith ACE inhibitols. Alrcady i t  has been shown that Ang-(l-7)
contr ibules to the antihypertensive e11ècts of blockade of the RAS in animals. This
observation st i l l  has to be conflrn,ed in patic-nts. Mcasurement olplasnta and t issue
levc ls  o f  Ang l ,  Ang I I  as  we l l  as  Ang- ( l -7 )  in  s tud ies  tha t  exp lo re  the  c l in ica l  e f fec ts
of ACE irrhibitors in paticr l ts may prol ide urorc insight in the role of Ang-(1-7).
Ang-(l-7) antagonize s Ang l l- indLrccd vasoconstr ict ions. Befbre onset of the studies
prcsented in this thesis, i t  was suggested that occupirt ion of the ATr receptor or Ang-
(l-7)- induced NO relcase be the rnecl.ranisms. l lorvever, from cel l  culture studies
otl .rer possible mechanisms arose. Wc speculatcd t l iat Ang-(l-7) prostaglandin release.
possibly through st imulat ion o1'AT: or BK B: receptors. nl ir1, also antagonizc Ang IL
As Ang-(l-7) lo'els are augrnentecl by ACE inhibit ion, an ACII inhibitor might in-
creasc these actions of Ang-(l-7). These hypotl ieses were addrcssed in a serie of
studies perfbrr led on aorl ic scgmcnts of norrnotensive rats dcscribed in chapters 4 and
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Summary, discussion & future directions
In Chapter 4, it is demonstrated that this antagonistic action of Ang-(1-7) is mediated
by prostaglandins. This could be the vasodilator prostacyclin, which is released from
culhred vascular smooth muscle cells upon stimulation with Ang-(l-7). The in-
volvement of NO in rut aorta is still doubtful. However, in other setups, with other
vessels types, it was demonstrated that also NO can play a role in the effects of Ang-
(1-7). This may in particular be the case in coronary vessels. Thus, each vessel type
responds differently to Ang-(l-7), which may have important clinical implications for
therapy with ACE inhibitors, but also for the validity of models in which the effects of
ACE inhibitors are tested.
In Chapter 5 the question through which receptor types Ang-(l-7) antagonizes are
involved in the antagonistic effect of Ang-(1-7) was addressed. AT1-receptors, ATz-
receptors, non-ATr/ATz receptors for Ang-(l-7), and BK 82 receptors were suggested
as candidates.
In the presence of the ACE inhibitor lisinopril, Ang-(l-7) decreased the responsive-
ness of rat thoracic aorta to Ang II through stimulation of ATz receptors and BK Bz
receptors. The involvement of ATz receptor can be explained, because prostaglandin
release upon stimulation of AT2 receptor with Ang-(1-7) has been observed in other
studies. For BK 82 receptors, a direct interaction of Ang-(l-7) has not been demon-
strated yet. Rather, Ang-(l-7) could induce BK release through AT2 receptors, tlus
stimulating BK 82 receptors.
A second way for Ang-(l-7) to antagonize Ang Il-induced vasoconstrictions i occu-
pation of the ATr receptor. Although the literature reported that in untreated rabbit
aorta this pathway for antagonism is used, in rat aorta, pretreatment with L-NMMA-
and indomethacin abolished the effect of Ang-(1-7). Apparently, Ane-(l-7) acts dif-
ferently on ATr receptors in rat aorta than in rabbit aorta. Therefore, the hypothesis
that Ang-(1-7) antagonizes Ang ll-induced vasoconstriction by binding to the ATr
receptor cannot be rejected.
The third pathway for Ang-(l-7) to antagonize, namely stimulation of D-Ala?-Ang-(l-
7)-sensitive non-ATr/ATz angiotensin receptors, is not involved in the antagonizing
effect ofAng-(1-7) on Ang II in rat aortic tissue. Therefore, the effects ofAng-(1-7)
on blood pressure through D-Ala7-Ang-(1-7)-sensitive r ceptors described in the lir
erature2'3 probably involve an interaction in tissues other than the vessel wall. How-
ever, the already mentioned vessel type- and species-related ifferences may be appli-
cable here as well. More research in different vessel types, such as coronary and re-
sistance vessels, is indispensible to obtain full insight into the direct effect of stimula-
tion of the non-ATr/ATz receptors on vasomotor function.
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Cltapter I
The effect of Ang-(1-7) mediated by prostaglandins was increased by ACE inhibitors
(Chapters 4 & 5). Therefore, the antihypertensive ffects of ACE inhibitors may be
facilitated by an increase in Ang-(l-7)-induced release ofvasodilating prostaglandins.
Recently, it r.vas hown that there is an inverse conelation between blood pressure and
Ang-( l-7) levels in patients with essential hypertension.a Also it was shown that Ang-
(l-7) contributes to the antihypertensive effects of RAS blockade.5 The interaction of
Ang-(1-7), lisinopril, prostaglandins, AT2 receptors, and BK Bz receptors may there-
fore importantly contribute to the clinical effects of ACE inhibitors.
As indicated in Chapter 2, not all of the effects of ACE inhibitors observed in rat
models for cardiovascular disease could be reproduced in patients. This is particularly
the case in studies to prevention of restenosis after angioplasty. It was suggested that
the presence of alternative Ang I to Ang II conversion pathways in human vascular
tissuc could be the cause of the lack in efÍictiveness of ACE inhibit ion. If Ang-(l-7)
plays a role during ACE inhibition, it is important to understand the relation between
Ang-(1-7) and alternativc conversion. In this thesis, this relation was studied. The
next paragraph is an outline ofthe data that provide relevant information.
8.2 Alternative conversion of Ang I to Ang ll by tissue chymase: escape from
ACE inhibitors
In Chapter 2 it was demonstrated that chymase is present in the vascular wall of hu-
man aileries. Consequently, the effect of Ang-(l-7) on contractions induced by the
ACE-specific Ang I analogue [Proro]-Ang I and the non-ACE Ang I analogue
lProrr,D-Alar"l-Ang I were compared. The results showed that Ang-(1-7) inhibits
ACE but not chymase. Both the presence of an altemative Ang I conversion pathway,
as the inefÍèctiveness of Ang-(1-7) to inhibit this conversion pathway may have con-
scquences for the local function ofAng-(1-7).
When compared to each other, the antagonistic effect of Ang-(1-7) on Ang Il-induced
contractions in human arteries (Chapter 3) is stronger than in rat aorta (Chapter 4).
In rat aorta, lisinopril is needed to enhance Ang-(l-7) to reach an effect that is compa-
rable to that in human arteries. This suggests that in rats more ACE is present han in
humans, which can be demonstrated in plasma (Fig. 1). In addition, Ang-(1-7) causes
a rightward shift in the dose-respons curve of Ang I in rat aorta (Fig. 2), which is not
observed in human artcrics (Chapter 3). A possible reason that humans have a lower
ACE activity is may be the presence of chymase . Such a highly active alternative Ang
I to Ang II conversion pathway is not present in the rat vasculature, and therefore, rats
would need higher amounts of local ACE. Unfortunately, no comparative data are
available on vascular ACE levels in rat and human arteries, so a definite conclusion
can not be drawn. Still, chymase influences the function of Ang-(1-7). The inability of
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Fig. 1: ACE activiy in rat and
human plasma, as measured by
the hippuryl-histidyl-leucine de-
gradation assay.
Fig. 2: (A) The effect of Ang-
(1-7) (lO) moVL) on vasocon-
strictions to angiotensin I (Ang
I) in isolated rat aortic rings, in
the presence of L-NMMA (l0a
mol/L). The vasoconstrictions
were expressed as a percentage
of the maximal response to Ang
I in the control group..(B) The
effect of Ang-(1-7) on EC5s
values (+/- SEM). A significant
difference in between EC56 val-
ues in control and Ang-(l-7)
pretreated rings was observed
(Mann-Whitney U test, n:4).
Ang-(l-7) to inhibit chymase (Chapter 3) explains why Ang-(1-7) does not cause a
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control -8.0 +/- 0.2 ^=n neo
Ang-(1-7) -7.4 +l- 0.1 í - ---
ACE inhibitor function of Ang-(l-7) is circumvented, and Ang II can still be formed
fromAngL
Chymase is present in the adventitia of blood vessels, and can not be inhibited by
ACE inhibitors or Ang-(l-7). This has important clinical implications. Firstly, the un-
rat plasma human plasma
Chapter 8
desired ovetproduction of Ang II in vascular tissue will persist in patients treated
with ACE inhibitor. Apafi from this, less Ang I rvill be avaible for the production of
Ang-( 1 -7) so that Ang II escapes from antagonism by Ang-( 1-7).
From the above, it becomes clear that ACE inhibition alone may not be sufficient to
efhciently block RAS activity in the human vessel wall. Amongst others, a sufficient
increase in production ofcounterregulating Ang-(l-7) may not be reached. To obtain
the beneficial effects of Ang-(1-7) in patients, an altemative way to increase Ang-(1-
7) levels in vascular tissue shouid be found. Expression ofpeptides through transfer of
genetic material (gene transfer or transfection) by vectors into the vascular tissue is a
promissing technique. This prompted the investigations on the ability of recombinant
Semliki Forest virus vector to tranfer genes into vascular tissue described in chapter 6
and 7. In the next paragraph, the data ofthese studies are summarized, and a possible
vector for Ang-(1-7) production is presented.
8.3 Viral vectors: towards a new approach for cardiovascular therapy through
increased Ang-(l -7) production
Gene transfer, or transfection, techniques offer the possibility to increase the produc-
tion ofproteins in cardiovascular tissue. Viral vectors currently represent the most ef-
ficient gene transfer systcms, and have been successfully employed in animal models
for the treatment ofrestenosis after angioplasty. Viral vectors have several drawbacks
such as lack of specificity for cell type and a late onset of gene expression. Transfec-
tion with vectors based on the Semliki F-orest virus (SFV) may overcome these draw-
backs. In Chapter 6 it is shown that SFV induces a faster expression offoreign genes
than adenoviral vectors in cultured VSMC. Furthermore, SFV selectively transfects
VSMC as compared to endothelial cells, and, therefore, it is not cltotoxic to endothe-
lial cells.
It was speculated that SFV selectively transfers genes into vessel segments in which
the endothelium has been disrupted by an angioplasty procedure. In Chapter 7 it is
demonstrated that SFV selectively transfects balloon-injured vessel segments. Theo-
retically, vectors based on SFV provide the possibility to intervene in the very early
processess involved in hypertrophy ofthe vessel wall after angioplasty. Furthermore,
SFV transfects VSMC, the main target cell, and leaves the endothelial cells unaf-
fected. An intact endothelium will reduce hypertrophy and, hence, the risk for reste-
ltos1s.
Once SFV has entered the target cell, the translational machinery of the host will be
completely occupied for the expression of the transferred genes. The target cell will
lose its physiological function and will perish eventually. Therefore, SFV is particu-
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esting paracrine hormone to be expressed after transfection during a coronary angio-
plasty procedure. It could inactivate the RAS and stimulate endothelial function which
ultimately should reduce the risk for restenosis and ischemic events. To accomplish
an effect ofAng-(1-7) overexpresseion, an Ang-(1-7)-coding sequence leading to suf-
ficiently high levels ofthe peptide has to be designed.
To explore the feasibil i ty ofusing a vector for expression ofAng-(1-7) in the vessel
wall, an Ang-(1-7)-coding recombinant SFV was designed, based on the genetic code
for angiotensinogen (for methods: see Appendix). In a pilot study, the expression of
SFV-Ang-(1-7) in cultured VSMC (rat aorta A7r5 cells) was measured with the use of
a radioimmunoassay for Ang-(l -7). A control vector carrying ïhe lacZ repofter gene
already augmented the level of Ang-(l-7) immunoreactivity, but SFV-Ang-(1-7) fur-
ther increased this level (Fig. 3).
Fig.  3:  Ang-(1-7)  immunereac-
tivity in culture medium of
VSMC (A7r5) at baseline, or
24 h after transfection with
SFVlacZ or SFV-Ang-(l -7)
(m.o.i. - 100), expressed rn
femtomoles (+ SEM) equiva-
lent to concentrations of Ang-
(1-7) in a standard curve. f: p <
0.05 vs. control, f,: p < 0.05 vs.
SFVlacZ, Mann-Whitney U,
n=4).
Although SFV-Ang-(1-7) increased Ang-(1-7) release, it is difficult to predict whether
the apparent Ang-(1-7) levels observed in this pilot were increased to a point that a
clinical effect could be expected. The Ang-(1-7) level may seem rather low to expect
a clinical effect. However, the SFV titers used were rather high and, therefore, may
already be cytotoxic in an early phase. Lowering the virus titers may optimize the ex-
pression of Ang-(l-7). In addition to this, the viral genome may be equipped with a
translational enhancer to increase foreign gene expression. Secondly, different VSMC
cell types may express Ang-(1-7) to different levels. Thirdly, the identity of the Ang-
(1-7) immunoreactive products has to be confirmed biochemically. These questions
have to be solved first before Ang-(l-7) expressing vectors based on the present Ang-
(1-7)-coding sequence can be applied in a rational manner in vivo. Once character-
ized, these vectors can either be used in models for cardiovascular diseases, such as
restenosis, or they can be used to explore the physiological relevance ofAng-(l-7),










Dr. Frans Boomsma of the Dept. of Internal Medicin, University of Rotterdam, is
geatly acknowledged for his suggestions and support in the practical procedures.
